Back

Cerenis Therapeutics announces that CARAT Phase 2 Study data on CER-001 have been presented at ACC annual meeting 2017

Cerenis Therapeutics announces that CARAT Phase 2 Study data on CER-001 have been presented at ACC annual meeting 2017

 

  • Primary endpoint, regression of coronary plaque in ACS, not met
  • Safety profile of CER-001 is reinforced
  • TANGO Phase 3 clinical study in patients with genetic HDL deficiencies is ongoing 

 

TOULOUSE, France and ANN ARBOR, Mich. (March 20, 2017 at 8.00 am CET) – Cerenis Therapeutics (FR0012616852 – CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative therapies for treating cardiovascular and metabolic diseases, announces that CARAT Phase 2 Study data on CER-001 in post-acute coronary syndrome (ACS) patients have been presented at the Annual American College of Cardiology (ACC) Scientific Sessions in Washington DC, USA.

Please find attached the full PDF file related to this information. 

About CER-001

CER-001 is an engineered complex of recombinant human apolipoprotein A-1 (apoA-I), the major structural protein of HDL, and phospholipids, designed to mimic the structure and function of natural, HDL.  It is intended to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport.

 

About Cerenis Therapeutics: www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of cardiovascular and metabolic diseases. Cerenis is developing a portfolio of therapies, including HDL mimetics for patients with HDL deficiency. Since its inception in 2005, the company has been funded by top-tier investors including Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance.  In March 2015 Cerenis completed an IPO on Euronext raising €53.4m.

●●●

CONTACTS

Cerenis  
CEO
Jean-Louis Dasseux
Tel: +33 (0)5 62 24 09 49
moc.s1506435835inere1506435835c@ofn1506435835i1506435835
NewCap 
Investor relations
Emmanuel Huynh / Louis-Victor Delouvrier
Media relations
Nicolas Merigeau

Tel: +33 (0)1 44 71 98 53
ue.pa1506435835cwen@1506435835siner1506435835ec1506435835

 


Source: Cerenis